Doxycycline

Generic Name: Doxycycline

Brand Names: Acticlate, Adoxa, Apprilon, Atridox, Doryx, Doxy, Doxycin, Lymepak, Mondoxyne, Monodox, Morgidox, Okebo, Oracea, Periostat, Targadox, Vibramycin

Drug Type: Small Molecule

Chemical Formula: C_₂₂H_₂₄N_₂O_₈

CAS Number: 564-25-0

Unique Ingredient Identifier: 334895S862

Background: Doxycycline is a broad-spectrum antibiotic synthetically derived from oxytetracycline. It is a second-generation tetracycline that was first discovered in 1967. Second-generation tetracyclines exhibit lesser toxicity than first-generation tetracyclines. Doxycycline is used to treat a wide variety of gram-positive and gram-negative bacterial infections. It is also used to treat acne and malaria.

Indication: Doxycycline is indicated for the treatment of various infections by gram-positive and gram-negative bacteria, aerobes and anaerobes, as well other types of bacteria, including:

It is also used to treat infections caused by the following gram-negative microorganisms:

Associated Conditions: Acinetobacter Infections, Anthrax, Bacterial Infection caused by Enterobacter aerogenes, Bartonellosis, Brucellosis, Campylobacter Infection, Chancroid, Chlamydia Trachomatis Infection, Early Lyme Disease, Granuloma Inguinale, Infection Due to Escherichia Coli, Inhalational Anthrax, Klebsiella Infections, Lymphogranuloma Venereum, Malaria caused by Plasmodium falciparum, Nongonococcal urethritis, Plague caused by Yersinia pestis, Psittacosis, Rectal infection caused by Chlamydia Trachomatis, Relapsing fever caused by Borrelia recurrentis, Respiratory Tract Infection Bacterial, Rickettsial infectious disorders, Severe Acne, Sexually Transmitted Infections (STIs), Shigella Infection, Trachoma inclusion conjunctivitis, Tularemia, Vibrio Cholerae Infection, Acute Intestinal amebiasis, Susceptible Bacterial Infections, Uncomplicated endocervical infection, Uncomplicated urethral infection

Clinical Trials

Doxycycline Outcomes in Lupus Erythematosus

Phase 4

Withdrawn

Conditions: Cardiovascular Disease

Interventions: Drug: Placebo
Drug: Doxycycline

First Posted Date: 2009-11-16

Last Posted Date: 2012-03-30

Lead Sponsor: Johns Hopkins University

Registration Number: NCT01014260

Locations: 🇺🇸
Johns Hopkins University SOM. 1830 East Monument St, Ste 7500, Baltimore, Maryland, United States

A Clinico-Pathological Study to Investigate the Possible Infective Causes of Non-Hodgkin Lymphoma of the Ocular Adnexae

Phase 2

Completed

Conditions: Non-Hodgkin Lymphoma

Interventions: Drug: doxycycline (tetracycline)

First Posted Date: 2009-11-10

Last Posted Date: 2013-11-25

Lead Sponsor: International Extranodal Lymphoma Study Group (IELSG)

Target Recruit Count: 54

Registration Number: NCT01010295

Locations: 🇨🇱
Hospital del Salvador, Providencia, Santiago, Chile
🇮🇹
Ospedale San Raffaele, Department of Oncology, Milan, Italy
🇮🇹
S. Matteo, Pavia, Italy

and more 3 locations

Doxycycline In Lymphangioleiomyomatosis (LAM)

Phase 4

Completed

Conditions: Lymphangioleiomyomatosis
Tuberous Sclerosis

Interventions: Drug: Placebo
Drug: Doxycycline

First Posted Date: 2009-10-05

Last Posted Date: 2015-12-02

Lead Sponsor: University of Nottingham

Target Recruit Count: 24

Registration Number: NCT00989742

Locations: 🇬🇧
Nottingham University Hospitals, Nottingham, United Kingdom

Treatment Failure of Chlamydial Infection in Males and Females in Youth Correctional Facilities

Phase 3

Completed

Conditions: Chlamydial Infection

Interventions: Drug: Doxycycline
Drug: Azithromycin

First Posted Date: 2009-09-18

Last Posted Date: 2015-03-18

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 567

Registration Number: NCT00980148

Locations: 🇺🇸
University of Alabama Hospital - Infectious Diseases, Birmingham, Alabama, United States
🇺🇸
Los Angeles County Department of Public Health - Sexually Transmitted Disease Program, Los Angeles, California, United States